Table 3B.
Prognostic factors in all BTCs: univariate analysis (therapy factors).
| Prognostic factor | n | Survival time (day) | P value | |
|---|---|---|---|---|
| Number of AI | < 13 > 13 |
19 30 |
313 535 |
0.040 |
| 5FU total volume | < 9750mg > 9750mg |
24 25 |
401 526 |
N.S |
| CDDP total volume | < 160mg > 160mg |
22 27 |
313 544 |
0.097 |
| Completion of RT | No Yes |
3 49 |
241 526 |
0.002 |
| Respose to AI+RT | No Yes |
31 21 |
371 1,151 |
<0.001 |
| Transition to CT | No Yes |
24 28 |
361.5 670 |
0.092 |
| Transition to GC | No Yes |
34 18 |
431 506 |
N.S |
| Transition to SP | No Yes |
48 4 |
463 629 |
N.S |
| Transition to GS | No Yes |
51 1 |
459 990 |
N.S |
| Transition to S-1 | No Yes |
49 3 |
453 965 |
N.S |
| Transition to UFT | No Yes |
24 28 |
459 NA |
N.S |
| Transition to Surgery | No Yes |
51 1 |
459 1,970 |
N.S |
| Biliary drainage | No Yes |
19 33 |
795 430 |
0.038 |
AI, intraarterial chemotherapy; RT, radiation therapy; CT, systemic chemotherapy; GC, gemcitabine plus cisplatin; SP, S-1 plus cisplatin; GS, gemcitabine plus S-1.